NOBITAN is aimed at the development of novel chemotherapeutic products exhibiting an enhanced safety and efficacy profile, through a selective targeting of inactive cytotoxic compounds toward tumor cells, and a smart release and local activation of the anticancer drug.
LEITAT’s contribuition: LEITAT will act as subcontractor to provide the technical expertise in the proof-of-concept packages and its know-how for the development and characterisation of the conjugate and will also provide support to management and exploitation activities in WP6.
Number of Contract: IUE/4066/2010
Coordiantor: Institut Univ. De Ciència i Tecnologia SA
Email LEITAT manager in charge: Izabel Alfany
Starts: September 2011
Duration: 24 months
|IUCT – Institut Univers. De Ciència i Tecnologia SA||Spain|
|JPT – Peptide Technologies GmbH||Germany|